Literature DB >> 3031072

A study of the mechanism of glucagon-induced protein phosphorylation in isolated rat hepatocytes using (Sp)-cAMPS and (Rp)-cAMPS, the stimulatory and inhibitory diastereomers of adenosine cyclic 3',5'-phosphorothioate.

P A Connelly, L H Botelho, R B Sisk, J C Garrison.   

Abstract

Maximal doses of glucagon increase the phosphorylation state of 12 cytosolic proteins in isolated hepatocytes from fasted rats (Garrison, J. C., and Wagner, J. D. (1982) J. Biol. Chem. 257, 13135-13143). Incubation of hepatocytes with lower concentrations of glucagon indicates that a hierarchy of substrates exists with the concentration of glucagon required for half-maximal increases in phosphorylation varying 5-15-fold. The proteins whose phosphorylation state is most sensitive to low concentrations of glucagon are pyruvate kinase and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase, both of which play key roles in the regulation of gluconeogenesis. Treatment of hepatocytes with (Sp)-cAMPS, the stimulatory diastereomer of adenosine cyclic 3',5'-phosphorothioate, mimics the response seen with glucagon. When hepatocytes are pretreated with the cAMP antagonist, (Rp)-cAMPS, the phosphorylation response is abolished at low concentrations of glucagon, and the dose of glucagon required for half-maximal stimulation of phosphorylation is increased 5-10-fold. The (Sp)-cAMPS-stimulated increases in phosphorylation state are also blunted by (Rp)-cAMPS. These results provide direct pharmacological evidence for the activation of the cAMP-dependent protein kinase in response to glucagon in the intact cell. Although low doses of glucagon appear to stimulate protein phosphorylation via the cAMP-dependent protein kinase, high doses of glucagon also cause a small increase in the concentration of free intracellular Ca2+ in hepatocytes. The glucagon-stimulated increases in the level of Ca2+ can be mimicked by (Sp)-cAMPS and inhibited by pretreatment with (Rp)-cAMPS. These results suggest that glucagon can elevate intracellular Ca2+ via cAMP and the cAMP-dependent protein kinase.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3031072

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Substrate-, hormone-, and cAMP-regulated cytochrome P450 degradation.

Authors:  E Eliasson; I Johansson; M Ingelman-Sundberg
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

2.  Different modulatory effects of elevated cyclic AMP on cytosolic Ca2+ spikes induced by phenylephrine or vasopressin in single rat hepatocytes.

Authors:  A Sanchez-Bueno; I Marrero; P H Cobbold
Journal:  Biochem J       Date:  1993-04-01       Impact factor: 3.857

3.  The early stimulation of glycolysis by epidermal growth factor in isolated rat hepatocytes is secondary to the glycogenolytic effect.

Authors:  I Quintana; M Grau; F Moreno; C Soler; I Ramírez; M Soley
Journal:  Biochem J       Date:  1995-06-15       Impact factor: 3.857

4.  Chronic opioid potentiates presynaptic but impairs postsynaptic N-methyl-D-aspartic acid receptor activity in spinal cords: implications for opioid hyperalgesia and tolerance.

Authors:  Yi-Lin Zhao; Shao-Rui Chen; Hong Chen; Hui-Lin Pan
Journal:  J Biol Chem       Date:  2012-06-07       Impact factor: 5.157

5.  Modulation of cytosolic-[Ca2+] oscillations in hepatocytes results from cross-talk among second messengers. The synergism between the alpha 1-adrenergic response, glucagon and cyclic AMP, and their antagonism by insulin and diacylglycerol manifest themselves in the control of the cytosolic-[Ca2+] oscillations.

Authors:  R Somogyi; M Zhao; J W Stucki
Journal:  Biochem J       Date:  1992-09-15       Impact factor: 3.857

6.  Two distinctly regulated events, priming and triggering, during retinoid-induced maturation and resistance of NB4 promyelocytic leukemia cell line.

Authors:  S Ruchaud; E Duprez; M C Gendron; G Houge; H G Genieser; B Jastorff; S O Doskeland; M Lanotte
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-30       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.